#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Moving Beyond Directly Observed Therapy for Tuberculosis


article has not abstract


Vyšlo v časopise: Moving Beyond Directly Observed Therapy for Tuberculosis. PLoS Med 12(9): e32767. doi:10.1371/journal.pmed.1001877
Kategorie: Perspective
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001877

Souhrn

article has not abstract


Zdroje

1. Selkon JB, Devadatta S, Kulkarni KG, Mitchison DA, Narayana AS, Nair CN, et al. The Emergence of Isoniazid-Resistant Cultures in Patients with Pulmonary Tuberculosis during Treatment with Isoniazid Alone or Isoniazid Plus Pas. Bull World Health Organ. 1964;31:273–94. 14253244

2. Yeager RL, Munroe WG, Dessau FI. Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. American review of tuberculosis. 1952;65(5):523–46. 14924175

3. Vall-Spinosa A, Lester W, Moulding T, Davidson PT, McClatchy JK. Rifampin in the treatment of drug-resistant mycobacterium tuberculosis infections. N Engl J Med. 1970;283(12):616–21. 4988918

4. Lee M, Cho SN, Barry CE 3rd, Song T, Kim Y, Jeong I. Linezolid for XDR-TB—Final Study Outcomes. N Engl J Med. 2015;373(3):290–1. doi: 10.1056/NEJMc1500286 26176401

5. Chaisson RE, Coberly JS, De Cock KM. DOTS and drug resistance: a silver lining to a darkening cloud. Int J Tuberc Lung Dis. 1999;3(1):1–3. 10094162

6. Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an idea. Lancet. 1995;345(8964):1545–8. 7677849

7. World Health Organization Global Tuberculosis Programme. Framework for effective tuberculosis control. WHO/TB/94.179. Geneva; WHO, 1994.

8. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med. 1993;328(8):521–6. 8381207

9. Duda SN, Farr AM, Lindegren ML, Blevins M, Wester CW, Wools-Kaloustian K, et al. Characteristics and comprehensiveness of adult HIV care and treatment programmes in Asia-Pacific, sub-Saharan Africa and the Americas: results of a site assessment conducted by the International epidemiologic Databases to Evaluate AIDS (IeDEA) Collaboration. J Int AIDS Soc. 2014;17:19045. doi: 10.7448/IAS.17.1.19045 25516092

10. Annas GJ. Control of tuberculosis—the law and the public's health. N Engl J Med. 1993;328(8):585–8. 8426636

11. Sagbakken M, Frich JC, Bjune GA, Porter JD. Ethical aspects of directly observed treatment for tuberculosis: a cross-cultural comparison. BMC Med Ethics. 2013;14:25. doi: 10.1186/1472-6939-14-25 23819555

12. Daftary A, Padayatchi N, O'Donnell M. Preferential adherence to antiretroviral therapy over tuberculosis treatment: a qualitative study of drug-resistant TB/HIV co-infected patients in South Africa. Glob Public Health. 2014;9(9):1107–16. doi: 10.1080/17441692.2014.934266 25035943

13. Nachega JB, Marconi VC, van Zyl GU, Gardner EM, Preiser W, Hong SY, et al. HIV treatment adherence, drug resistance, virologic failure: evolving concepts. Infect Disord Drug Targets. 2011;11(2):167–74. 21406048

14. van den Boogaard J, Boeree MJ, Kibiki GS, Aarnoutse RE. The complexity of the adherence-response relationship in tuberculosis treatment: why are we still in the dark and how can we get out? Trop Med Int Health. 2011;16(6):693–8. doi: 10.1111/j.1365-3156.2011.02755.x 21375681

15. Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney GB, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994;330(17):1179–84. 8139628

16. Kenyon TA, Mwasekaga MJ, Huebner R, Rumisha D, Binkin N, Maganu E. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. Int J Tuberc Lung Dis. 1999;3(1):4–11. 10094163

17. Volmink J, Garner P. Directly observed therapy for treating tuberculosis. The Cochrane database of systematic reviews. 2007;(4):CD003343. 17943789

18. Pope DS, Chaisson RE. TB treatment: as simple as DOT? Int J Tuberc Lung Dis. 2003;7(7):611–5. 12870680

19. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis. 2011;204(12):1951–9. doi: 10.1093/infdis/jir658 22021624

20. Ankomah P, Levin BR. Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinum. PLoS Pathog. 2012;8(1):e1002487. doi: 10.1371/journal.ppat.1002487 22253599

21. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993;328(8):527–32. 8426619

22. Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197 Suppl 3:S272–8. doi: 10.1086/533415 18447613

23. Petersen ML, LeDell E, Schwab J, Sarovar V, Gross R, Reynolds N, et al. Super Learner Analysis of Electronic Adherence Data Improves Viral Prediction and May Provide Strategies for Selective HIV RNA Monitoring. J Acquir Immune Defic Syndr. 2015;69(1):109–18. doi: 10.1097/QAI.0000000000000548 25942462

24. Curry FJ. Encounters in training clinic support staff. Chest. 1975;68(3 Suppl):462–5. 1157565

Štítky
Interné lekárstvo

Článok vyšiel v časopise

PLOS Medicine


2015 Číslo 9
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Aktuální možnosti diagnostiky a léčby litiáz
nový kurz
Autori: MUDr. Tomáš Ürge, PhD.

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#